Experimental Gene Therapy Aims To Reverse Vision Loss By Rejuvenating Aging Eye Cells
A landmark human trial has begun testing whether an experimental gene therapy can make aging eye cells behave more like younger ones and restore lost vision. US biotech company Life Biosciences has administered its first dose of ER-100, a therapy designed to reverse age-related damage in retinal ganglion cells.
These cells form the optic nerve that connects the eye to the brain and normally cannot regenerate once damaged. Diseases such as glaucoma silently injure these nerves, often causing irreversible vision loss that current treatments can only slow, not repair. ER-100 is designed to challenge that limitation.
How The Experimental Therapy Works
The treatment uses a harmless viral vector to deliver three specific genes into retinal ganglion cells. Once activated, these genes produce proteins that partially reprogram the cells, encouraging them to function more like younger, healthier tissue, based on earlier animal studies.
A key safety feature is a genetic switch controlled by a common antibiotic taken orally by participants. The reprogramming genes remain active only while the drug is present in the body, allowing doctors to halt their activity if concerning side effects emerge. The company stresses that ER-100 does not edit or replace a person’s existing genes.
From Mouse Experiments To Human Eyes
Harvard geneticist David Sinclair and colleagues first reported in 2020 that a similar approach could restore some vision in older or injured mice. Their work suggested that aging may be driven in part by the loss of epigenetic information, the chemical markers that regulate how DNA is read inside cells.
Life Biosciences licensed this technology and spent several years testing ER-100 in laboratory models and non-human primates. In January 2024, the US Food and Drug Administration cleared the company to begin a Phase 1 clinical trial focused primarily on safety in people with severe vision loss.
Details Of The First Clinical Trial
The initial study will enroll up to 18 participants, beginning with 12 people diagnosed with open-angle glaucoma, the most common form of the disease. An additional six patients may be included if they have optic nerve damage caused by nonarteritic anterior ischemic optic neuropathy.
Each volunteer will receive a one-time injection of the viral vector into the eye and then take the activating antibiotic for several weeks. Researchers will test different dose levels, increasing them only if earlier participants tolerate the therapy. All participants will be monitored for at least five years.
Promise And Potential Dangers
Preclinical data suggest that ER-100 can restore some function in damaged retinal cells, raising hopes that even partial vision loss could be improved. Supporters argue that, if proven safe, the same strategy could eventually be adapted to treat other age-related diseases affecting different organs.
However, cellular reprogramming carries serious and partly unknown risks, including the possibility of uncontrolled cell growth or cancerous changes. Critics warn that altering gene activity on this scale in human eyes may have consequences that mouse and primate studies cannot fully predict.
Scientific Debate Over Aging Reversal
Some researchers question whether the trial is beginning too soon, given the remaining gaps in understanding how epigenetic reprogramming behaves in complex human tissues. Stem cell expert Paul Knoepfler has described the approach as “extraordinarily high-risk” and doubts that any benefits will be lasting without also lowering eye pressure in glaucoma patients.
There is also no consensus on what it would truly mean to “reverse aging” in a specific cell type. Scientists use various biological clocks to measure aging, including DNA methylation, gene expression and cellular function, but it remains unclear which measures matter most for meaningful clinical benefit.
Managing Expectations And Next Steps
The current Phase 1 trial is small and designed primarily to identify safety issues, not to prove effectiveness. Early vision data will be closely monitored, but they will not be sufficient to determine whether ER-100 can reliably restore sight or meaningfully reverse age-related cellular changes.
Sinclair’s broader aging theory, and his public enthusiasm for longevity interventions, have attracted skepticism in the past. The coming years of follow-up in this trial will provide some of the first hard human evidence on whether partial epigenetic reprogramming can safely influence disease, or whether the risks ultimately outweigh the potential benefits.
